Presentation is loading. Please wait.

Presentation is loading. Please wait.

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial  Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Published byRachel Barreto Modified over 5 years ago

Similar presentations

Presentation on theme: "Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial  Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,"— Presentation transcript:

1 Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial 
Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD, Filippo de Marinis, MD, James Chih-Hsin Yang, MD, Heather A. Wakelee, MD, Takashi Seto, MD, Yi-Long Wu, MD, Silvia Novello, MD, Erszébet Juhász, MD, Osvaldo Arén, MD, Yan Sun, MD, Thomas Schmelter, PhD, Teng Jin Ong, MD, Carol Peña, PhD, Egbert F. Smit, PhD, Tony S. Mok  Journal of Thoracic Oncology  Volume 10, Issue 12, Pages (December 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Patient disposition in the Monotherapy admInistration of Sorafenib in patientS wIth nOn–small-cell luNg cancer (MISSION) trial. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan–Meier analyses of (A) overall survival, (B) progression-free survival, and (C) time to progression in patients with non–small-cell lung cancer (NSCLC) receiving sorafenib or placebo as third-/fourth-line treatment. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Subgroup analysis for overall survival, progression-free survival, and time to progression. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival (OS) and progression-free survival (PFS) among patients providing samples for biomarker analysis. (A) OS, (B) PFS, (C) OS for patients with epidermal growth factor receptor (EGFR) mutations, and (D) PFS for patients with EGFR mutations. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial  Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,"

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google